Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0A7NB
|
||||
| Former ID |
DCL000985
|
||||
| Drug Name |
Siplizumab
|
||||
| Synonyms |
Siplizumab (USAN/INN)
|
||||
| Drug Type |
Antibody
|
||||
| Indication | Lymphoma [ICD9: 202.8, 208.9; ICD10:C81-C86] | Phase 2 | [1] | ||
| Cancer; Psoriasis [ICD9: 140-229, 696; ICD10:L40] | Discontinued in Phase 2 | [2] | |||
| Company |
Medlmmune; AstraZeneca
|
||||
| CAS Number |
CAS 288392-69-8
|
||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | T-cell surface antigen CD2 | Target Info | [2] | ||
| KEGG Pathway | Cell adhesion molecules (CAMs) | ||||
| Hematopoietic cell lineage | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| IL2 Signaling Pathway | |||||
| Reactome | Cell surface interactions at the vascular wall | ||||
| WikiPathways | Cell surface interactions at the vascular wall | ||||
| References | |||||
| REF 1 | Safety profile of intravenous and subcutaneous siplizumab, an anti-CD2 monoclonal antibody, for the treatment of plaque psoriasis: results of two randomized, double-blind, placebo-controlled studies.Int J Dermatol. 2010 Jul;49(7):818-28. | ||||
| REF 2 | Emerging drugs for moderate-to-severe psoriasis. Expert Opin Emerg Drugs. 2005 Feb;10(1):35-52. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.